Tandem Diabetes Care is trying to rebuild a slower-growing insulin-pump franchise around a pharmacy pay-as-you-go contract rather than the old four-year durable-medical-equipment check. That shift is the entire June-quarter story. Hardware still ships, but recognition of the pump itself is thinner and the cash is meant to arrive later through supplies. The investment debate is whether lifetime-value recapture and a smaller Mobi form factor can offset Insulet's much faster tubeless scale.
Pharmacy already accounts for 10 percent of United States sales after one full quarter of the new contract. Management estimated the missing upfront pump check reduced the print by about $8 million. Gross margin still reached 57 percent, helped by pharmacy pricing and rising Mobi volume. The same quarter carried shortages from the sole third-party infusion-set supplier. Those two forces pull in opposite directions. Mix is lifting the income statement while supply is capping the unit engine that the new model needs.
The company reaffirmed full-year sales near $1.07 billion and kept adjusted EBITDA, a cash-earnings proxy that adds back stock compensation and certain charges, inside a mid-single-digit margin band. Cash and short-term investments still exceed $450 million after a zero-coupon 2032 note issue, a larger CeQur stake, and a Roche settlement payment. The next several quarters resolve whether pharmacy mix, a pending Mobi tubeless filing, and easier infusion-set flow can turn a still-lossy franchise into self-funding growth. The alternative is that Insulet simply keeps taking the incremental patient.